How can we improve the carbon footprint of IBD clinical care?

IF 2.4 Q3 GASTROENTEROLOGY & HEPATOLOGY Frontline Gastroenterology Pub Date : 2024-03-05 DOI:10.1136/flgastro-2023-102564
Isabel Carbery, Gauraang Bhatnagar, Rachel Cooney, Christian Selinger
{"title":"How can we improve the carbon footprint of IBD clinical care?","authors":"Isabel Carbery, Gauraang Bhatnagar, Rachel Cooney, Christian Selinger","doi":"10.1136/flgastro-2023-102564","DOIUrl":null,"url":null,"abstract":"The carbon footprint of the National Health Service (NHS) is estimated to be responsible for 5.9% of the total UK carbon footprint. The NHS has committed to reach carbon net zero by 2040, and therefore, all healthcare professionals have a role to play in identifying ways to help achieve this goal within their individual clinical areas. While specific research focusing on the carbon footprint of inflammatory bowel disease (IBD) care is limited, by combining principles of sustainable healthcare with work done in other healthcare areas, we can start to develop ideas to inspire our own sustainable IBD care. The aim of this review article is to examine each part of the IBD care pathway and consider where improvements in sustainability can be made or future research should be focused.","PeriodicalId":46937,"journal":{"name":"Frontline Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontline Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/flgastro-2023-102564","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The carbon footprint of the National Health Service (NHS) is estimated to be responsible for 5.9% of the total UK carbon footprint. The NHS has committed to reach carbon net zero by 2040, and therefore, all healthcare professionals have a role to play in identifying ways to help achieve this goal within their individual clinical areas. While specific research focusing on the carbon footprint of inflammatory bowel disease (IBD) care is limited, by combining principles of sustainable healthcare with work done in other healthcare areas, we can start to develop ideas to inspire our own sustainable IBD care. The aim of this review article is to examine each part of the IBD care pathway and consider where improvements in sustainability can be made or future research should be focused.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
如何改善 IBD 临床护理的碳足迹?
据估计,英国国家医疗服务系统(NHS)的碳足迹占英国碳足迹总量的 5.9%。英国国家医疗服务体系(NHS)承诺到 2040 年实现零碳排放,因此,所有医疗保健专业人员都有责任在各自的临床领域内找出帮助实现这一目标的方法。虽然针对炎症性肠病(IBD)护理碳足迹的具体研究有限,但通过将可持续医疗保健原则与其他医疗保健领域的工作相结合,我们可以开始提出一些想法,以启发我们自己的可持续 IBD 护理。这篇综述文章旨在研究 IBD 护理路径的各个环节,并考虑可在哪些方面改进可持续发展或未来研究的重点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontline Gastroenterology
Frontline Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.70
自引率
11.50%
发文量
93
期刊介绍: Frontline Gastroenterology publishes articles that accelerate adoption of innovative and best practice in the fields of gastroenterology and hepatology. Frontline Gastroenterology is especially interested in articles on multidisciplinary research and care, focusing on both retrospective assessments of novel models of care as well as putative future directions of best practice. Specifically Frontline Gastroenterology publishes articles in the domains of clinical quality, patient experience, service provision and medical education.
期刊最新文献
Neuroendocrine tumours found at endoscopy: diagnosis and staging British Society of Gastroenterology Endoscopic Retrograde Cholangiopancreatography (ERCP) Quality Improvement Programme: minimum service standards and good practice statements Investigation of abnormal liver blood tests in patients with inflammatory bowel disease Effectiveness of risankizumab induction and maintenance therapy for refractory Crohn’s disease: a real-world experience from a preapproval access programme and early access to medicines scheme #FGDebate: addressing regional variations in care and outcomes for patients with liver disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1